A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA).

Lipika Goyal,Hui Zheng,Matthew B. Yurgelun,Thomas Adam Abrams,Eunice L. Kwak,James M. Cleary,Michelle Knowles,Eileen Regan,Amy Gisondi,Susan Sheehan,Anna Khachatryan,Valentina Nardi,Darrell R. Borger,Gabriel Dan Duda,Andrew X. Zhu

A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA).

2015

Lipika Goyal
Hui Zheng
Matthew B. Yurgelun
Thomas Adam Abrams
Eunice L. Kwak
James M. Cleary
Michelle Knowles
Eileen Regan
Amy Gisondi
Susan Sheehan
Anna Khachatryan
Valentina Nardi
Darrell R. Borger
Gabriel Dan Duda
Andrew X. Zhu

e15124 Background: Advanced CCA carries a poor prognosis, and no standard treatment exists beyond the first line gemcitabine/platinum-based regimen. We performed a single arm phase II and biomarker...

Keywords:

Oncology
Pathology
Biomarker (medicine)
Internal medicine
Cabozantinib
Medicine
poor prognosis
Regimen
Standard treatment
first line
Gemcitabine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations